Suzano sets sales record in 2024 with new mill in Mato Grosso do Sul state and acquisition in the U.S.
13.2.2025 00:31:00 EET | Business Wire | Press release
Suzano, the world’s largest pulp producer, announces its quarterly results for both the final quarter (4Q24) and the full year (2024). Pulp and paper sales reached a new record of 12.3 million tonnes, rising 7% on 2023, mainly driven by the additional capacity from the new pulp mill in Ribas do Rio Pardo in Mato Grosso do Sul state. Further capacity from the recent acquisition of paperboard mills in the United States has also contributed to the record sales volume.
The higher sales volumes and favorable exchange rates boosting export revenues resulted in net revenues of R$47.4 billion in 2024, 19% higher than in 2023. Adjusted EBITDA grew 31%, to R$23.8 billion, while operational cash generation increased 40%, reaching R$16.2 billion. Suzano reported a net loss of R$6.7 billion due to the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. There is no immediate cash impact of this accounting adjustment and the potential cash effect will only occur at debt and hedging maturity.
Suzano invested R$17.1 billion in 2024, with R$4.5 billion specifically allocated to the new mill - the Cerrado Project - in Ribas do Rio Pardo. The world's largest single pulp production line began operations on July 21 and completed its learning curve process in less than six months, well ahead of expectations and setting a record timeline in the industry's history. The new mill has also contributed to reducing Suzano's pulp cash cost by 6% to R$828/tonne in 2024 versus the prior year.
Beto Abreu, CEO of Suzano, commented:
“We successfully completed our Cerrado Project and made significant strides in our strategy, with the acquisition of assets in the U.S. and a stake in Lenzing, the Austria-based textiles business. Despite these investments, we ended 2024 with lower net leverage than the prior year, reflecting Suzano's discipline in capital allocation, operational competitiveness and financial strength”.
Suzano’s net leverage in U.S. dollars fell from 3.1 times in December 2023 to 2.9 times at the end of 2024, in line with Suzano’s commitment to execute its largest-ever capital investment project within the limits established in the company’s policy. In addition to maintaining robust investment plans, Suzano allocated R$2.8 billion to fund its share buyback program and paying a total of R$1.5 billion as interest on equity to its shareholders.
In the year of its centenary, Suzano reached the mark of 56,000 direct and indirect employees and embarked on an ambitious commitment to invest up to US$100 million over a ten-year period in initiatives focusing on research, knowledge generation and education for sustainability, in collaboration with renowned international institutions, including the University of Cambridge and the non-governmental organization IUCN, among others.
Suzano's central goal is to drive global efforts to protect and restore nature by developing expertise and leadership in sustainability, and accelerating research and education in conservation, climate change, and water resource management.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212112172/en/
Contacts
Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release
Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom